Background The aim of the study was to evaluate the efficacy and safety of entecavir (ETV)
among chronic hepatitis B (CHB) nucleos (t) ide-naive Egyptian patients. Methods Forty …

Methods A total of 227 patients were included. PVR was defined as a more than 1 log 10
IU/mL decline in detectable serum hepatitis B virus (HBV) DNA by polymerase chain …

Background: Long-term data of uninterrupted entecavir for treatment-naı¨ ve CHB patients in
clinical practice is lacking. Aim: To examine the virological and biochemical responses …

Aim Data from registration trials with highly selective patients have shown that hepatitis B
envelope antigen (HBeAg)-positive patients with chronic hepatitis B respond well to …

AIM: To analysis the factors that predict the response to entecavir therapy in chronic hepatitis
patients with hepatitis B virus (HBV) genotype C. METHODS: Fifty patients [hepatitis B e …

Background & Aims We investigated the rate of relapse of hepatitis B virus (HBV) infection
after entecavir therapy for chronic hepatitis B and the association between level of hepatitis …

Abstract Background and Aim: Entecavir has demonstrated clinical efficacy for chronic
hepatitis B. This study evaluated the efficacy and safety of entecavir in nucleoside‐naive …

Purpose Entecavir demonstrated superior virologic and biochemical benefits over
lamivudine at 48 weeks in nucleoside-naïve Chinese patients with chronic hepatitis B …

Abstract Background/Aims Chronic hepatitis B has a high prevalence (> 8%) in China. We
compared the safety and efficacy of entecavir with that of lamivudine for the treatment of …

Methods This study analyzed 44 consecutive CHB patients (age, 44.6±11.4 years,
mean±SD; men, 63.6%; positive hepatitis B envelope antigen (HBeAg) at baseline, 56.8%; …